Use of Wisteria Floribunda Agglutinin-Positive Human Mac-2 Binding Protein in Assessing Risk of Hepatocellular Carcinoma Due to Hepatitis B Virus

Medicine (United States)

Volumn 95, Issue 14, 2016, Pages

  Heo, Ja Yoon ^a   Kim, Seung Up ^a,b   Kim, Beom Kyung ^a,b   Park, Jun Yong ^a,b   Kim, Do Young ^a,b   Ahn, Sang Hoon ^a,b   Park, Young Nyun ^a   Ahn, Sung Soo ^a   Han, Kwang Hyub ^a,b   Kim, Hyon Suk ^c  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University   (South Korea)

^c Yonsei University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

AGGLUTININ; BINDING PROTEIN; UNCLASSIFIED DRUG; WISTERIA FLORIBUNDA AGGLUTININ POSITIVE HUMAN MAC 2 BINDING PROTEIN; BIOLOGICAL MARKER; MEMBRANE PROTEIN; N ACETYLGLUCOSAMINE RECEPTOR; PLANT LECTIN; TAA90K PROTEIN, HUMAN; TUMOR ANTIGEN; WISTERIA LECTIN;

ADULT; AGE; ANTIVIRAL THERAPY; ARTICLE; CANCER GROWTH; CANCER RISK; CHRONIC HEPATITIS B; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FOLLOW UP; HEPATITIS B VIRUS; HISTOLOGY; HUMAN; HUMAN TISSUE; INCIDENCE; LIVER CELL CARCINOMA; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; THROMBOCYTE COUNT; WISTERIA; BLOOD; CARCINOMA, HEPATOCELLULAR; COMPLICATION; CROSS-SECTIONAL STUDY; HEPATITIS B; LIVER NEOPLASMS; MIDDLE AGED; PROCEDURES; VIROLOGY;

ADULT; ANTIGENS, NEOPLASM; BIOMARKERS; CARCINOMA, HEPATOCELLULAR; CROSS-SECTIONAL STUDIES; FEMALE; HEPATITIS B, CHRONIC; HUMANS; LIVER NEOPLASMS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; PLANT LECTINS; PREDICTIVE VALUE OF TESTS; RECEPTORS, N-ACETYLGLUCOSAMINE; RETROSPECTIVE STUDIES; RISK ASSESSMENT;

EID: 84964601626     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000003328     Document Type: Article

References (40)

1. WHO. Guidelines Approved by the Guidelines Review Committee. Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection. Geneva: World Health Organization; 2015.
2. Tang CM, Yau TO, Yu J. Management of chronic hepatitis B infection: current treatment guidelines, challenges, and new developments. World J Gastroenterol. 2014;20:6262-6278.
3. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2095-2128.
4. McMahon BJ. The natural history of chronic hepatitis B virus infection. Hepatology. 2009;49:S45-S55.
5. Calvaruso V, Craxì A. Regression of fibrosis after HBV antiviral therapy. Is cirrhosis reversible? Liver Int. 2014;34:85-90.
6. Chang T-T, Liaw Y-F, Wu S-S, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology. 2010;52:886-893.
7. Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013;381:468-475.
8. Lai CL, Yuen MF. Prevention of hepatitis B virus-related hepatocel-lular carcinoma with antiviral therapy. Hepatology. 2013;57:399-408.
9. Bolondi L, Sofia S, Siringo S, et al. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut. 2001;48:251-259.
10. Rockey DC, Caldwell SH, Goodman ZD, et al. Liver biopsy. Hepatology. 2009;49:1017-1044.
11. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med. 2001;344:495-500.
12. Castera L, Pinzani M. Non-invasive assessment of liver fibrosis: are we ready? Lancet. 2010;375:1419-1420.
13. Kuno A, Ikehara Y, Tanaka Y, et al. A serum "sweet-doughnut" protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis. Sci Rep. 2013;3:1065.
14. Toshima T, Shirabe K, Ikegami T, et al. A novel serum marker, glycosylated Wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA()-M2BP), for assessing liver fibrosis. J Gastroen-terol. 2015;50:76-84.
15. Yamasaki K, Tateyama M, Abiru S, et al. Elevated serum levels of Wisteria floribunda agglutinin-positive human Mac-2 binding protein predict the development of hepatocellular carcinoma in hepatitis C patients. Hepatology. 2014;60:1563-1570.
16. Abe M, Miyake T, Kuno A, et al. Association between Wisteria floribunda agglutinin-positive Mac-2 binding protein and the fibrosis stage of non-Alcoholic fatty liver disease. J Gastroenterol. 2015;50:776-784.
17. Umemura T, Joshita S, Sekiguchi T, et al. Serum Wisteria floribunda agglutinin-positive mac-2-binding protein level predicts liver fibrosis and prognosis in primary biliary cirrhosis. Am J Gastroenterol. 2015;110:857-864.
18. Batts KP, Ludwig J. Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol. 1995;19:1409-1417.
19. Kuno A, Sato T, Shimazaki H, et al. Reconstruction of a robust glycodiagnostic agent supported by multiple lectin-Assisted glycan profiling. Proteomics Clin Appl. 2013;7:642-647.
20. Kim JH, Kim MN, Han KH, et al. Clinical application of transient elastography in patients with chronic viral hepatitis receiving antiviral treatment. Liver Int. 2015;35:1103-1115.
21. Kim MN, Kim SU, Kim BK, et al. Increased risk of hepatocellular carcinoma in chronic hepatitis B patients with transient elastogra-phy-defined subclinical cirrhosis. Hepatology. 2015;61:1851-1859.
22. Park MS, Kim SU, Kim BK, et al. Prognostic value of the combined use of transient elastography and fibrotest in patients with chronic hepatitis B. Liver Int. 2015;35:455-462.
23. Seo YS, Kim MY, Kim SU, et al. Accuracy of transient elastography in assessing liver fibrosis in chronic viral hepatitis: a multicentre, retrospective study. Liver Int. 2015;35:2246-2255.
24. Korean Liver Cancer Study Group and National Cancer Center, Korea. Practice guidelines for management of hepatocellular carcinoma 2009. Korean J Hepatol. 2009;15:391-423.
25. Artini M, Natoli C, Tinari N, et al. Elevated serum levels of 90K/MAC-2 BP predict unresponsiveness to alpha-interferon therapy in chronic HCV hepatitis patients. J Hepatol. 1996;25:212-217.
26. Sasaki T, Brakebusch C, Engel J, et al. Mac-2 binding protein is a cell-Adhesive protein of the extracellular matrix which self-Assembles into ring-like structures and binds beta1 integrins, collagens and fibronectin. Embo J. 1998;17:1606-1613.
27. Troeger JS, Mederacke I, Gwak GY, et al. Deactivation of hepatic stellate cells during liver fibrosis resolution in mice. Gastroenterol-ogy. 2012;143:1073-1083e1022.
28. Callewaert N, Van Vlierberghe H, Van Hecke A, et al. Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics. Nat Med. 2004;10:429-434.
29. Ura K, Furusyo N, Ogawa E, et al. Serum WFA-M2BP is a non-invasive liver fibrosis marker that can predict the efficacy of direct-Acting anti-viral-based triple therapy for chronic hepatitis C. Aliment Pharmacol Ther. 2016;43:114-124.
30. Nishikawa H, Enomoto H, Iwata Y, et al. Clinical significance of serum Wisteria floribunda agglutinin positive Mac-2-binding protein level and high-sensitivity C-reactive protein concentration in autoimmune hepatitis. Hepatol Res. 2015[Epub ahead of print].
31. Lee HW, Yoo EJ, Kim BK, et al. Prediction of development of liver-related events by transient elastography in hepatitis B patients with complete virological response on antiviral therapy. Am J Gastroenterol. 2014;109:1241-1249.
32. Lee HW, Chon YE, Kim SU, et al. Predicting liver-related events using transient elastography in chronic hepatitis C patients with sustained virological response. Gut Liver. 2015[Epub ahead of print].
33. You SC, Kim KJ, Kim SU, et al. Factors associated with significant liver fibrosis assessed using transient elastography in general population. World J Gastroenterol. 2015;21:1158-1166.
34. Yo IK, Kwon OS, Park JW, et al. The factors associated with longitudinal changes in liver stiffness in patients with chronic hepatitis B. Clin Mol Hepatol. 2015;21:32-40.
35. Kim BK, Kim SU, Kim HS, et al. Prospective validation of FibroTest in comparison with liver stiffness for predicting liver fibrosis in Asian subjects with chronic hepatitis B. PLoS One. 2012;7:e35825.
36. Poynard T, Mathurin P, Lai CL, et al. A comparison of fibrosis progression in chronic liver diseases. J Hepatol. 2003;38:257-265.
37. Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. Hepatology. 2002;36:S47-S56.
38. Heathcote EJ. Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines. Hepatology. 2000;31:1005-1013.
39. Sasaki R, Yamasaki K, Abiru S, et al. Serum Wisteria floribunda agglutinin-positive mac-2 binding protein values predict the development of hepatocellular carcinoma among patients with chronic hepatitis C after sustained virological response. PLoS One. 2015;10:e0129053.
40. Tamaki N, Kurosaki M, Kuno A, et al. Wisteria floribunda agglutinin positive human Mac-2-binding protein as a predictor of hepatocellular carcinoma development in chronic hepatitis C patients. Hepatol Res. 2015;45:E82-E88.